Synairgen

Synairgen is a biotechnology company based in Southampton, UK, focused on developing treatments for respiratory diseases, particularly those caused by viral infections. Its primary focus is on utilizing the body's own immune system to fight off viruses. The company's lead drug candidate is SNG001, an inhaled formulation of interferon beta-1a. SNG001 is being investigated for its potential to reduce the severity of lower respiratory tract illnesses caused by viruses such as influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 (the virus that causes COVID-19). Synairgen is publicly traded on the London Stock Exchange (LSE: SYGN). The company was founded in 2003 by researchers at the University of Southampton.